PRISMAP has just returned from the annual congress of the European Association of Nuclear Medicine (EANM – Barcelona, 6–8 October 2025). With 9,431 congress participants (including online participants) and 2,991 abstracts submitted, this year's congress set a new record. On the occasion of the 40th anniversary of the EANM Congress, PRISMAP and its representatives were more present than ever, underlining the growing importance of PRISMAP.

The highlight of PRISMAP's contributions to the congress was a dedicated session on Sunday, 5 October 2025. As part of a thematic block on EU projects, PRISMAP was able to share its results and perspectives. To familiarise the audience with PRISMAP, Thierry Stora from CERN first presented the structure and scope of PRISMAP, the number of projects funded and the development prospects. Eleni Gourni, Bern, Switzerland, reported on her experiences as a PRISMAP user with Sc-47 from PRISMAP. She described the process from applying for a PRISMAP user project to its successful implementation. Finally, Clemens Decristoforo from Innsbruck, Austria, explained how PRISMAP was involved in networking activities with a focus on harmonisation and standardisation. The session ended with a lively discussion among interested users about logistics and supply chains, the application process and other questions about the scope and future of the project, underscoring the great inte

rest and need for novel radionuclides for medical applications.

PRISMAP plays an important role in current political decision-making processes at European Commission level, as was also made clear at the EANM Congress. According to Paola Erba, President of EANM, and Wim Oyen (former President and Board Member of EANM), PRISMAP acts as an EU platform for research in the field of biomedical radionuclides and is in contact with various institutions, in particular the European Medicines Agency.

In addition, PRISMAP was represented by a number of speakers, poster presenters and chairs from the consortium, as well as by users who presented their projects made possible by PRISMAP's services. We are particularly pleased that three of our presentations were classified as ‘top rated oral presentations’ by the EANM:

• N. Kumar, E. Gourni et al: Targeted Radionuclide Therapy of Prostate Cancer using a177 Lu- and47 Sc-labeled Gastrin-Releasing Peptide Receptor Antagonist. Evaluation as Monotherapy and in Combination with Everolimus
• A. Gustafsson, M. Nestor et al: Tb, or Not Tb - Exploring Terbium-161 for CD44v6Targeted Radionuclide Therapy
• M. Salek, J. W. Engle et al: Small cyclotron production of n.c.a.103 Pd from Rh targets for targeted radionuclide therapy